Cara Therapeutics News Releases http://ir.caratherapeutics.com/ Cara Therapeutics News Releases en Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-present-jefferies-2019-healthcare-conference STAMFORD, Conn. , May 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Fri, 31 May 2019 07:00:00 -0400 Cara Therapeutics News Releases 10351 Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-positive-results-kalm-1-pivotal - Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) – - Statistically significant improvement in key secondary endpoint of proportion of patients with four Wed, 29 May 2019 07:00:00 -0400 Cara Therapeutics News Releases 10321 Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-present-bank-america-merrill-lynch-2019-health STAMFORD, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Wed, 08 May 2019 16:01:00 -0400 Cara Therapeutics News Releases 10301 Cara Therapeutics Reports First Quarter 2019 Financial Results http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-reports-first-quarter-2019-financial-results – Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , May 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting Tue, 07 May 2019 16:01:00 -0400 Cara Therapeutics News Releases 10286 Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019 http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announce-first-quarter-2019-financial-results STAMFORD, Conn. , April 30, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today Tue, 30 Apr 2019 16:01:00 -0400 Cara Therapeutics News Releases 10276 Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-present-18th-annual-needham-healthcare STAMFORD, Conn. , April 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, Tue, 02 Apr 2019 16:01:00 -0400 Cara Therapeutics News Releases 10251 Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-reports-fourth-quarter-and-full-year-2018 Conference call today at 4:30 p.m. ET STAMFORD, Conn. , March 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting Tue, 12 Mar 2019 16:01:00 -0400 Cara Therapeutics News Releases 10206 Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019 http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announce-fourth-quarter-and-full-year-2018 STAMFORD, Conn. , March 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today Tue, 05 Mar 2019 16:01:00 -0500 Cara Therapeutics News Releases 10176 Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-completes-enrollment-kalm-1-pivotal-phase-3 Top-line Data Readout Expected in Q2, 2019 STAMFORD, Conn. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively Mon, 07 Jan 2019 07:00:00 -0500 Cara Therapeutics News Releases 10131 Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-no-modifications-trial-size-after -  Trial continues as planned with enrollment target of 350 patients  - -  Top-line data readout expected in the first half of 2019  - STAMFORD, Conn. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new Wed, 02 Jan 2019 07:00:00 -0500 Cara Therapeutics News Releases 10101